NEC and Transgene Announce a Collaboration in the Field of Individualized Cancer Immunotherapy, Leveraging NEC's AI and Transgene's myvac Platform
TOKYO, Oct, 30 2018 - (JCN Newswire) - NEC Corporation (TSE: 6701) and Transgene today announced the signing of a Memorandum of Understanding (MOU) for a strategic collaboration aimed at the treatment of solid cancers. The companies will cooperate in clinically assessing the predictive capabilities of NEC's artificial intelligence (AI) and the therapeutic potential of Transgene's myvac(1) MVA-based viral vector platform in an individualized immunotherapy for the treatment of solid cancers. The experimental products from this collaboration are expected to enter clinical trials in 2019.
NEC and Transgene will co-invest in the first stage of development of an individualized immunotherapy, which includes clinical trials focusing on ovarian cancer and HPV-negative head and neck cancer.
Immunotherapy is rapidly becoming the treatment of choice to fight cancer as it activates the patient's own immune system to attack cancer cells.
NEC and Transgene have capitalized on the recent progress in AI and advances in genome sequencing to create individualized immunotherapy, which is adapted to the unique characteristics of each patient's mutational landscape as well as their predicted immune responses. The product is based on a viral vector (MVA) developed by Transgene with a proven clinical safety track record and is known for its efficient immunogenicity and anti-tumor efficacy in patients.
The viral vector will be used to target neoantigens identified using NEC's proprietary algorithm. NEC has been developing solutions in the drug discovery field for close to two decades. NEC's neoantigen prediction system(2) was developed and validated based on publicly available databases, as well as internal wet lab datasets, some of which were already used to identify clinically relevant antigens in other oncology indications.
These planned clinical trials leverage the world-leading expertise and technologies of a network of companies and research centers, including:
NEC's cutting-edge AI technology, "NEC the WISE"(3), for identifying and prioritizing patient-specific neoantigens, and Transgene's unrivaled MVA-based, viral vector technology and the myvac platform.
"The emerging personalized medicine field holds great potential for the application of NEC's core technology, and we are pleased to be working with Transgene with the goal of developing state-of-the-art personalized immunotherapies," said Motoo Nishihara, Senior Vice President, Head of NEC Laboratories.
"Engaging the body's own immune system in the fight against cancer has shown great promise and sparked unprecedented interest among oncology drug makers. This makes it imperative for NEC to become part of the immunotherapy race as soon as possible," said Osamu Fujikawa, Senior Vice President, Business Innovation Unit, NEC Corporation.
"This collaboration brings together artificial intelligence and our expertise in viral vector engineering to enable the development of a truly innovative treatment based on the myvac platform. We believe that our collaboration with NEC will allow us to provide an efficacious and robust therapy for the many patients who have solid tumors and could benefit from this cutting-edge individualized approach, and to successfully advance the development of the myvac platform to the market" said Eric Quemeneur, Pharm.D., Ph.D., Executive VP, Chief Scientific Officer of Transgene.
myvac is a viral vector (MVA) based, individualized immunotherapy platform that has been developed by Transgene to target solid tumors. The myvac-derived products are designed to stimulate the patient's immune system, recognize and destroy tumors using the patient's own cancer specific genetic mutations. Transgene has set up an innovative network that combines bioengineering, digital transformation, established vectorization know-how and unique manufacturing capabilities.
(2) NEC's Neoantigen Prediction System
NEC's neoantigen prediction utilizes its proprietary AI, such as graph-based relational learning, which is combined with other sources of data to discover candidate neoantigen targets. NEC comprehensively evaluates the candidate neoantigens with a primary focus placed on its in-house MHC-binding affinity prediction. These allow NEC to effectively prioritize the numerous candidate neoantigens identified in a single patient.
(3) NEC the WISE
NEC the WISE is a term for the Company's cutting-edge portfolio of AI technologies.
NEC announces new AI technology brand, "NEC the WISE"
NEC's AI Research:
About NEC Corporation
NEC Corporation is a leader in the integration of IT and network technologies that benefit businesses and people around the world. The NEC Group globally provides "Solutions for Society" that promote the safety, security efficiency and fairness of society. Under the company's corporate message of "Orchestrating a brighter world," NEC aims to help solve a wide range of challenging issues and to create new social value for the changing world of tomorrow. For more information, visit NEC at https://www.nec.com.
Source: NEC Corporation
Sectors: Enterprise IT, BioTech
Copyright ©2019 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.
|(from left: Eric Quemeneur, Pharm.D., Ph.D., Executive VP, Chief Scientific Officer, Transgene; Kaidre Bendjama, Transgene; Motoo Nishihara, Senior Vice President, Head of NEC Laboratories; Osamu Fujikawa, Senior Vice President, Business Innovation Unit, NEC Corporation)|
Latest Press Release
More Latest Release >>
DENSO to Mass-produce Automotive Alternators Equipped with Newly Developed High-efficiency Diodes
May 23, 2019 18:19 JST
Tohoku University and DOCOMO Launch Research Project to Develop Artificial-intelligence Technology for Periodontal Disease Detection
May 23, 2019 16:29 JST
MHPS Receives Contract for Complete Renovation of Flue Gas Desulfurization System at the Dětmarovice Power Station in the Czech Republic
May 23, 2019 15:15 JST
The University of Tokyo, Toyota, and TRENDE to Begin Testing of Next-generation Electricity System
May 23, 2019 14:03 JST
KDDI and SUMITOMO to enter Myanmar's Mobile Game Industry
May 22, 2019 15:00 JST
Showa Denko Group Revises CSR Policy
May 22, 2019 12:00 JST
DENSO and Aisan Studying the Possibility of Strengthening Competitiveness in Powertrain and Future Growth Areas
May 20, 2019 18:40 JST
Honda Begins Joint Research with Center for Information and Neural Networks (CiNet) to Strengthen its Study of Humans in the Areas of Mobility and Robotics
May 20, 2019 18:30 JST
Lexus LC Takes 24th Position Overall at QF Race for Nurburgring 24 Hours Endurance Race
May 20, 2019 17:07 JST
"Science Based Targets (SBT) Initiative" Approves Eisai's Greenhouse Gas Reduction Targets
May 17, 2019 16:34 JST
Toyota Rolls Out New Supra
May 17, 2019 15:49 JST
DOCOMO Develops Safe, Blade-free Drone Propelled with Ultrasonic Vibrations
May 17, 2019 12:08 JST
Hitachi Automotive Systems' EV Inverter Adopted for the e-tron, Audi's First Mass Production Electric Vehicle
May 17, 2019 11:40 JST
NEC Awarded Intelligent Transportation System Project in Oman
May 17, 2019 11:15 JST
Eisai to Present Data on Oncology Pipeline and Products at 55th Asco Annual Meeting
May 16, 2019 08:37 JST
Toyota: The Master Craftsmanship of the Century, Japan's Only Chauffeur-Driven Car
May 15, 2019 16:19 JST
NEC and CSC e-Governance Services Form a Strategic Alliance to Deliver Innovative Digital Services for Rural Areas in India
May 15, 2019 13:12 JST
Mitsubishi Shipbuilding Holds Christening Ceremony for Next-Generation LNG Carrier "BUSHU MARU"
May 15, 2019 12:14 JST
MHPS Receives Order for Two H-25 Gas Turbines for Major Chinese Paper Firm Lee & Man Paper Manufacturing Ltd.
May 15, 2019 11:37 JST
Mitsubishi Corporation: Production Underway at Cameron LNG
May 14, 2019 20:01 JST